insomnia insomnia
Conditions
Interventions
Subjects are administered one tablet once a day before bedtime for the first week.
If there is no improvement in the Athens Insomnia Scale values during the second week, the dose will be 7.5mg, 1.5 ta
an acute care hospital iisomnia older orexin receptor antagonist
Sponsors
Saito Taeko
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inpatients 65 years of age or older who have given consent to participate in studyand who meet the diagnosis of insomnia.
Exclusion criteria
Exclusion criteria: Physically critical patients Patients with terminal condisitons Hypersensitivity to the components of orexin recepter antagonist Patients with narcolepsy or catalepsy Severe hepatic dysfunction,renal dysfunction, respiratory dysfunction Patients who have difficulty obtain consent to participate in reserch due to cognitive decline Patients receiving orexin receptor antagonist and patients with a history of orexin receptor antagonist administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation by score on the Athens Insomnia Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| Observation record of sleep state and daytime activity record by writing in the nursing record TMIG Index of Competence Japanese version NEECHAM Confusion State Scale | — |
Contacts
Public Contactsaito taeko
Nippon Medical School Chiba Hokusoh Hospital
Outcome results
None listed